# Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

> **NCT05617859** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Effectiveness
- Sexuality

## Interventions

- **DRUG:** Lenvatinib mesylate capsule

## Key facts

- **NCT ID:** NCT05617859
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617859, "Lenvatinib for Advanced Bone and Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05617859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*